Literature DB >> 34554463

Biologia futura: animal testing in drug development-the past, the present and the future.

Miklós Sántha1.   

Abstract

Animal experiments have served to improve our knowledge on diseases and treatment approaches since ancient times. Today, animal experiments are widely used in medical, biomedical and veterinary research, and are essential means of drug development and preclinical testing, including toxicology and safety studies. Recently, great efforts have been made to replace animal experiments with in vitro organoid culture methods and in silico predictions, in agreement with the 3R strategy to "reduce, refine and replace" animals in experimental testing, as outlined by the European Commission. Here we present a mini-review on the development of animal testing, as well as on alternative in vitro and in silico methods, that may at least partly replace animal experiments in the near future.
© 2020. The Author(s).

Entities:  

Keywords:  3D organoid culture; Animal experiments; Drug development; Gene modifications; In silico prediction; Phenotype analysis; Transgenesis

Mesh:

Year:  2020        PMID: 34554463     DOI: 10.1007/s42977-020-00050-4

Source DB:  PubMed          Journal:  Biol Futur        ISSN: 2676-8607


  35 in total

1.  Mouse chimeras obtained by the injection of cells into the blastocyst.

Authors:  R L Gardner
Journal:  Nature       Date:  1968-11-09       Impact factor: 49.962

2.  Analysis of homologous recombination in cultured mammalian cells.

Authors:  K Folger; K Thomas; M R Capecchi
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1984

3.  Establishment in culture of pluripotential cells from mouse embryos.

Authors:  M J Evans; M H Kaufman
Journal:  Nature       Date:  1981-07-09       Impact factor: 49.962

4.  Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Authors:  Paul W Burridge; Yong Fuga Li; Elena Matsa; Haodi Wu; Sang-Ging Ong; Arun Sharma; Alexandra Holmström; Alex C Chang; Michael J Coronado; Antje D Ebert; Joshua W Knowles; Melinda L Telli; Ronald M Witteles; Helen M Blau; Daniel Bernstein; Russ B Altman; Joseph C Wu
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

5.  Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Paul W Burridge; Sebastian Diecke; Elena Matsa; Arun Sharma; Haodi Wu; Joseph C Wu
Journal:  Methods Mol Biol       Date:  2016

6.  Breaking the code of DNA binding specificity of TAL-type III effectors.

Authors:  Jens Boch; Heidi Scholze; Sebastian Schornack; Angelika Landgraf; Simone Hahn; Sabine Kay; Thomas Lahaye; Anja Nickstadt; Ulla Bonas
Journal:  Science       Date:  2009-12-11       Impact factor: 47.728

7.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

8.  Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice.

Authors:  M J Callow; L J Stoltzfus; R M Lawn; E M Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 9.  Understanding gene functions and disease mechanisms: Phenotyping pipelines in the German Mouse Clinic.

Authors:  Helmut Fuchs; Juan Antonio Aguilar-Pimentel; Oana V Amarie; Lore Becker; Julia Calzada-Wack; Yi-Li Cho; Lillian Garrett; Sabine M Hölter; Martin Irmler; Martin Kistler; Markus Kraiger; Philipp Mayer-Kuckuk; Kristin Moreth; Birgit Rathkolb; Jan Rozman; Patricia da Silva Buttkus; Irina Treise; Annemarie Zimprich; Kristine Gampe; Christine Hutterer; Claudia Stöger; Stefanie Leuchtenberger; Holger Maier; Manuel Miller; Angelika Scheideler; Moya Wu; Johannes Beckers; Raffi Bekeredjian; Markus Brielmeier; Dirk H Busch; Martin Klingenspor; Thomas Klopstock; Markus Ollert; Carsten Schmidt-Weber; Tobias Stöger; Eckhard Wolf; Wolfgang Wurst; Ali Önder Yildirim; Andreas Zimmer; Valérie Gailus-Durner; Martin Hrabě de Angelis
Journal:  Behav Brain Res       Date:  2017-09-29       Impact factor: 3.332

10.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.

Authors:  John G Doench; Nicolo Fusi; Meagan Sullender; Mudra Hegde; Emma W Vaimberg; Jennifer Listgarten; Katherine F Donovan; Ian Smith; Zuzana Tothova; Craig Wilen; Robert Orchard; Herbert W Virgin; David E Root
Journal:  Nat Biotechnol       Date:  2016-01-18       Impact factor: 54.908

View more
  2 in total

Review 1.  Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models.

Authors:  Luigino Calzetta; Elena Pistocchini; Beatrice Ludovica Ritondo; Francesco Cavalli; Francesca Camardelli; Paola Rogliani
Journal:  Heliyon       Date:  2022-06-22

2.  Use of Cytokine Mix-, Imiquimod-, and Serum-Induced Monoculture and Lipopolysaccharide- and Interferon Gamma-Treated Co-Culture to Establish In Vitro Psoriasis-like Inflammation Models.

Authors:  Katarzyna Bocheńska; Marta Moskot; Magdalena Gabig-Cimińska
Journal:  Cells       Date:  2021-11-02       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.